Michel Vounatsos

2017

In 2017, Michel Vounatsos earned a total compensation of $13.7M as Chief Executive Officer at Biogen, a 136% increase compared to previous year.

Compensation breakdown

Change in Pension Value and Nonqualified Deferred Compensation Earnings$18,881
Non-Equity Incentive Plan$2,502,500
Salary$1,087,885
Stock Awards$9,868,540
Other$186,567
Total$13,664,373

Vounatsos received $9.9M in stock awards, accounting for 72% of the total pay in 2017.

Vounatsos also received $18.9K of change in pension value and nonqualified deferred compensation earnings, $2.5M in non-equity incentive plan, $1.1M in salary and $186.6K in other compensation.

Rankings

In 2017, Michel Vounatsos' compensation ranked 350th out of 14,666 executives tracked by ExecPay. In other words, Vounatsos earned more than 97.6% of executives.

ClassificationRankingPercentile
All
350
out of 14,666
98th
Division
Manufacturing
112
out of 5,772
98th
Major group
Chemicals And Allied Products
29
out of 2,075
99th
Industry group
Drugs
20
out of 1,731
99th
Industry
Biological Products, Except Diagnostic Substances
3
out of 313
99th
Source: SEC filing on April 27, 2018.

Vounatsos' colleagues

We found eight more compensation records of executives who worked with Michel Vounatsos at Biogen in 2017.

2017

George Scangos

Biogen

Chief Executive Officer

2017

Kenneth DiPietro

Biogen

Former Executive Vice President, Human Resources

2017

Michael Ehlers

Biogen

Executive Vice President, Research & Development

2017

Susan Alexander

Biogen

Chief Legal Officer

2017

Paul McKenzie

Biogen

Executive Vice President, Pharmaceutical Operations & Technology

2017

Paul Clancy

Biogen

Chief Financial Officer

2017

Gregory Covino

Biogen

Chief Accounting Officer

2017

Jeffrey Capello

Biogen

Chief Financial Officer

News

You may also like